ONCTERNAL THERAPEUTICS INC ONCT 深 滬
已收盤 12-02 16:00:00 美东时间
0.5266
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.5266
- 總市值 155.85万
- 52周最高 13.14
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.5266
- 委 比 0.00%
- 總股本 295.96万
- 歷史最高 211.20
- 量 比 0
- 振 幅 0.00%
- 歷史最低 5.22
- 每 手 1
- 風險率 1.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations
Oncternal Therapeutics sold its zilovertamab and ONCT-808 programs to Ho’ola Therapeutics for $3 million upfront, plus up to $65 million in milestone payments. Oncternal will wind down operations under新CEO Craig Jalbert.
07-01 12:00
【天风医药杨松团队|首次覆盖】基石药业-B：迈向管线2.0，ROR1 ADC潜力十足
（来源：市场投研资讯） 基石药业是一家专注于抗肿瘤药物研发的创新驱动型生物医药企业，截至2025 年2月，公司已成功上市4款创新药、获批16项新...
03-12 15:01
Oncternal Therapeutics Announces Workforce Reduction and Executive Changes
Oncternal Therapeutics ( ($ONCT) ) has provided an update. Oncternal Therapeuti...
2024-11-15 06:28
快讯 | Oncternal Therapeutics Inc：四名Oncternal员工将在探索战略选择的过程中以兼职身份继续工作。
Oncternal Therapeutics Inc: Four Oncternal Employees Will Remain in a Part-Time...
2024-11-15 06:09
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Gritstone Bio (NASDAQ:GRTS) shares moved upwards by 42.6% to $0.08 dur...
2024-10-15 20:08
Oncternal Therapeutics Restructures Amid Clinical Setbacks
Oncternal Therapeutics ( ($ONCT) ) has shared an announcement. Oncternal Therap...
2024-09-13 05:18
快讯 | Oncternal Therapeutics：员工减少约10人
Oncternal Therapeutics : Workforce Reduction of About 10 Employees
2024-09-13 05:04
Brookline Capital Downgrades Oncternal Therapeutics to Hold
Brookline Capital analyst Kemp Dolliver downgrades Oncternal Therapeutics (NASDAQ:ONCT) from Buy to Hold.
2024-09-12 23:16
Oncternal plunges on portfolio shakeup
Shares of nanocap biotech Oncternal Therapeutics (NASDAQ:ONCT) fell sharply in the morning hours on Thursday after the cancer drug developer announced plans to halt its product development activities ...
2024-09-12 22:09
HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Lowers Price Target to $18
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and lowers the price target from $19 to $18.
2024-08-12 17:52
